To identify new structure-function correlations in the ␥ domain of streptokinase, mutants were generated by error-prone random mutagenesis of the ␥ domain and its adjoining region in the  domain followed by functional screening specifically for substrate plasminogen activation. Single-site mutants derived from various multipoint mutation clusters identified the importance of discrete residues in the ␥ domain that are important for substrate processing. Among the various residues, aspartate at position 328 was identified as critical for substrate human plasminogen activation through extensive mutagenesis of its side chain, namely D328R, D328H, D328N, and D328A. Other mutants found to be important in substrate plasminogen activation were, namely, R319H, N339S, K334A, K334E, and L335Q. When examined for their 1:1 interaction with human plasmin, these mutants were found to retain the nativelike high affinity for plasmin and also to generate amidolytic activity with partner plasminogen in a manner similar to wild type streptokinase. Moreover, cofactor activities of the mutants precomplexed with plasmin against microplasminogen as the substrate as well as in silico modeling studies suggested that the region 315-340 of the ␥ domain interacts with the serine protease domain of the macromolecular substrate. Overall, our results identify the presence of a substrate specific exosite in the ␥ domain of streptokinase.Streptokinase (SK), 3 secreted by several -hemolytic group C (1, 2) strains of the genus Streptococcus, is a flexible multidomain protein (3,4). SK is often employed as a thrombolytic drug because it has the ability to activate human plasminogen (HPG), a zymogen, to its enzymatically active form, the serine protease, plasmin (HPN) (5, 6). However, unlike the physiological HPG activators such as tPA and urokinase, SK first forms a high affinity equimolar complex with HPG that results in the conformational activation of HPG to form SK⅐HPG* that specifically recruits substrate HPG and cleaves the Arg-561-Val-562 bond in substrate HPG molecules, thereby converting these into HPN (Pathway I, conformational activation pathway) (5, 6). The N-terminal Ile of SK has been demonstrated to play a critically important role in the activation of the "partner" after the formation of the 1:1 binary complex between SK and HPG (7-9). In addition, through several elegant studies on the mechanism of zymogen activation in the SK⅐HPG complex, it has been shown that HPN exhibits much higher affinity for SK compared with HPG, as a result of which an intermolecular exchange reaction takes place wherein the SK⅐HPN activates free substrate HPG molecules into HPN (10, 11). SK can also directly act as a co-factor for HPN, which upon complexation with HPN (12) (Pathway II, direct proteolytic activation pathway) virtually transforms the trypsin-like broad substrate specificity of HPN toward the cleavage of the scissile peptide bond, Arg-561-Val-562, in the incoming substrate HPG (12, 13).The mechanism by which SK alters the substrate specifi...